Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Semin Arthritis Rheum ; 65: 152379, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38241913

RESUMO

AIM: To explore if patient global assessment (PGA) is associated with inflammation over time and if associations are explained by other measures of disease activity and function in patients with idiopathic inflammatory myopathies (IIM). METHODS: PGA and systemic inflammatory markers prospectively collected over five years were retrieved from the International MyoNet registry for 1200 patients with IIM. Associations between PGA, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and creatine kinase (CK) were analyzed using mixed models. Mediation analysis was used to test if the association between PGA and inflammatory markers during the first year of observation could be explained by measures of disease activity and function. RESULTS: PGA improved, and inflammatory markers decreased during the first year of observation. In the mixed models, high levels of inflammatory markers were associated with worse PGA in both men and women across time points during five years of observation. In men, but not in women, the association between elevated ESR, CRP and poorer PGA was explained by measures of function and disease activity. With a few exceptions, the association between improved PGA and reduced inflammatory markers was partially mediated by improvements in all measures of function and disease activity. CONCLUSION: Increased levels of systemic inflammation are associated with poorer PGA in patients with IIM. In addition to known benefits of lowered inflammation, these findings emphasize the need to reduce systemic inflammation to improve subjective health in patients with IIM. Furthermore, the results demonstrate the importance of incorporating PGA as an outcome measure in clinical practice and clinical trials.


Assuntos
Miosite , Masculino , Humanos , Feminino , Estudos Longitudinais , Miosite/complicações , Inflamação , Avaliação de Resultados em Cuidados de Saúde , Sedimentação Sanguínea
2.
Rheumatology (Oxford) ; 60(2): 907-910, 2021 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-33175137

RESUMO

OBJECTIVE: The COVID-19 pandemic and the subsequent effects on healthcare systems is having a significant effect on the management of long-term autoimmune conditions. The aim of this study was to assess the problems faced by patients with idiopathic inflammatory myopathies (IIM). METHODS: An anonymized eSurvey was carried out with a focus on effects on disease control, continuity of medical care, drug procurance and prevalent fears in the patient population. RESULTS: Of the 608 participants (81.1% female, median (s.d.) age 57 (13.9) years), dermatomyositis was the most frequent subtype (247, 40.6%). Patients reported health-related problems attributable to the COVID-19 pandemic (n = 195, 32.1%); specifically 102 (52.3%) required increase in medicines, and 35 (18%) required hospitalization for disease-related complications. Over half (52.7%) of the surveyed patients were receiving glucocorticoids and/or had underlying cardiovascular risk factors (53.8%), placing them at higher risk for severe COVID-19. Almost one in four patients faced hurdles in procuring medicines. Physiotherapy, critical in the management of IIM, was disrupted in 214 (35.2%). One quarter (159, 26.1%) experienced difficulty in contacting their specialist, and 30 (4.9%) were unable to do so. Most (69.6%) were supportive of the increased use of remote consultations to maintain continuity of medical care during the pandemic. CONCLUSION: This large descriptive study suggests that the COVID-19 pandemic has incurred a detrimental effect on continuity of medical care for many patients with IIM. There is concern that delays and omissions in clinical care may potentially translate to poorer outcomes in the future.


Assuntos
Antirreumáticos/uso terapêutico , COVID-19 , Continuidade da Assistência ao Paciente , Miosite/terapia , Modalidades de Fisioterapia , Telemedicina , Tempo para o Tratamento , Adulto , Idoso , Dermatomiosite/fisiopatologia , Dermatomiosite/psicologia , Dermatomiosite/terapia , Progressão da Doença , Medo/psicologia , Feminino , Glucocorticoides/uso terapêutico , Conhecimentos, Atitudes e Prática em Saúde , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Hospitalização/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Miosite/fisiopatologia , Miosite/psicologia , Miosite de Corpos de Inclusão/fisiopatologia , Miosite de Corpos de Inclusão/psicologia , Miosite de Corpos de Inclusão/terapia , Polimiosite/fisiopatologia , Polimiosite/psicologia , Polimiosite/terapia , SARS-CoV-2 , Inquéritos e Questionários , Reino Unido , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA